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S-Adenosyl-L-methionine (AdoMet):arsenic(III) meth-
yltransferase, purified from liver cytosol of adult male
Fischer 344 rats, catalyzes transfer of a methyl group
from AdoMet to trivalent arsenicals producing methyl-
ated and dimethylated arsenicals. The kinetics of pro-
duction of methylated arsenicals in reaction mixtures
containing enzyme, AdoMet, dithiothreitol, glutathione
(GSH), and arsenite are consistent with a scheme in
which monomethylated arsenical produced from arsen-
ite is the substrate for a second methylation reaction
that yields dimethylated arsenical. The mRNA for this
protein predicts a 369-amino acid residue protein (mo-
lecular mass 41056) that contains common methyltrans-
ferase sequence motifs. Its sequence is similar to Cyt19,
a putative methyltransferase, expressed in human and
mouse tissues. Reverse transcription-polymerase chain
reaction detects S-adenosyl-L-methionine:arsenic(III)
methyltransferase mRNA in rat tissues and in HepG2
cells, a human cell line that methylates arsenite and
methylarsonous acid. S-Adenosyl-L-methionine:arsenic-
(III) methyltransferase mRNA is not detected in UROtsa
cells, an immortalized human urothelial cell line that
does not methylate arsenite. Because methylation of ar-
senic is a critical feature of its metabolism, character-
ization of this enzyme will improve our understanding
of this metalloid’s metabolism and its actions as a toxin
and a carcinogen.
In many species, including humans, exposure to inorganic
arsenic results in urinary excretion of methylated and dimethy-
lated arsenicals (1–3). Cullen and co-workers (4) summarized
the conversion of inorganic arsenic into these methylated prod-
ucts in a reaction scheme which incorporates oxidative methy-
lation and the cycling of arsenic between the pentavalent
(AsV)1 and trivalent (AsIII) oxidation states,
AsVO4
3  2e3 AsIIIO3
3  CH3
3 CH3AsVO3




  2e3 (CH3)2AsIIIO  CH3
 (Eq. 1)
Because reduction of arsenic to trivalency is a prerequisite for
its oxidative methylation, pentavalent arsenicals are reduced
by endogenous thiols such as glutathione (GSH) (5, 6) or by AsV
reductases (7–9). A protein has been purified from rabbit liver
cytosol that catalyzes the methylation of both arsenite and
methylarsonous acid (10, 11); however, this protein has not
been sequenced. These activities are designated arsenite meth-
yltransferase (EC 2.1.1.137) and methylarsonite methyltrans-
ferase (EC 2.1.1.138), respectively. This protein (estimated mo-
lecular mass 60 kDa) uses S-adenosyl-L-methionine (AdoMet)
as the methyl group donor. The methylation of arsenite by this
protein is stimulated by a monothiol (GSH) and the methyla-
tion of methylarsonous acid is highly stimulated by a dithiol,
dithiothreitol (DTT).
The methylation of arsenic has been commonly regarded as a
mechanism for its detoxification (12). However, recent research
has shown that methylated arsenicals that contain AsIII are
important intermediates in the metabolism of inorganic ar-
senic. Methylated arsenicals that contain AsIII are found in the
urine of individuals who chronically consume drinking water
that contains inorganic arsenic and in cells cultured in the
presence of arsenite (13–18). These AsIII-containing metabo-
lites are more cytotoxic and genotoxic than either arsenate or
arsenite (19–21). Methylated arsenicals that contain AsIII are
also more potent than arsenite as inhibitors of the activities of
various enzymes, including GSH reductase (22, 23), thiore-
doxin reductase (24, 25), and pyruvate dehydrogenase (26).
These results suggest that the methylation process can be
properly regarded as a means for the activation of inorganic
arsenic to more reactive and toxic species. Consequently, char-
acterization of enzymes that catalyze formation of methylated
arsenicals is an important step in understanding the conse-
quences of chronic exposure to inorganic arsenic.
Although there are extensive data on the kinetics of forma-
tion of methylated arsenicals in in vitro systems containing
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crude cytosolic preparations or purified enzyme, in cultured
cells, and in intact animals, little is known about the properties
of the enzymes that catalyze the methylation reactions. The
work reported here describes the purification of a novel protein
from rat liver cytosol that catalyzes the time-dependent forma-
tion of methylated and dimethylated arsenicals in reaction
mixtures that contain the purified protein, arsenite, GSH,
DTT, and AdoMet. Mass spectrometric sequencing of peptides
generated from this protein indicates a high degree of homology
with Cyt19, a putative methyltransferase of unknown function
that is expressed in mouse and human tissues. Using degener-
ate oligonucleotide primers based on the amino acid sequence
of peptides from the purified protein, the complete nucleotide
sequence of the mRNA encoding the protein has been deter-
mined. This novel protein is designated S-adenosyl-L-methio-
nine:arsenic(III) methyltransferase. The mRNA for the protein
is expressed in a variety of rat tissues and in HepG2 cells, a
human hepatoma cell line. However, it is not expressed in
UROtsa cells, an SV40 large T antigen-immortalized human
urothelial line (27), that do not methylate inorganic arsenic.
EXPERIMENTAL PROCEDURES
Materials—Unless otherwise noted, all reagents were obtained from
Sigma. HepG2 cells were obtained from ATCC and UROtsa cells were
obtained from Dr. N. Unimye, Department of Urology, School of Medi-
cine, West Virginia University. Radiolabeled arsenite ([73As]iAsIII) was
prepared by the procedure of Reay and Asher (28) from radiolabeled
arsenate [73As]iAsV obtained from the Los Alamos Meson Production
Facility (Los Alamos, NM). The methylated arsenical, methylarsine
oxide (MAsIIIO), was synthesized and characterized as previously de-
scribed (22).
Enzyme Purification—Male Fischer 344 rats (4 to 6 weeks old) from
Charles River Laboratories were maintained in a 12-h light, 12-h dark
photocycle at 21  2 °C with free access to PMI 5001 Rodent Chow (PMI
Nutrition International) and tap water. Rats were euthanized by car-
diac exsanguination under nembutal anesthesia. All subsequent steps
were performed at 4 °C. Livers were perfused in situ with 154 mM NaCl,
removed, blotted, and weighed. Pooled livers (up to 150 g) were homog-
enized in a buffer containing 25 mM Tris, 5 mM GSH, 1 mM DTT, and
250 mM sucrose, pH 8.3, at a tissue-to-buffer ratio of 1:5 (w/v) using a
glass-Teflon homogenizer. The homogenate was centrifuged at
110,000  g for 45 min to prepare a cytosolic fraction. After removal of
the lipid layer, the cytosolic fraction was adjusted to pH 5 by dropwise
addition of 1 M acetic acid. The acidified cytosol was immediately
centrifuged at 10,000  g for 15 min; the supernatant was removed and
adjusted to pH 8.3 by the dropwise addition of 1 M ammonium hydrox-
ide. The treated supernatant could be stored overnight at 4 °C without
loss of arsenic methyltransferase activity.
Treated supernatant was chromatofocused on a column of Polybuffer
Exchanger PBE94 gel (Amersham Biosciences Inc.) that was eluted
with Polybuffer 96 diluted 1:9 (v/v) in 25 mM Tris, 5 mM GSH, and 1 mM
DTT, pH 6. The arsenic methylating activities of eluate fractions were
assessed using a thin layer chromatography (TLC) method for the
separation of 73As-labeled products. Briefly, [73As]iAsIII (final concen-
tration 0.1 M AsIII) and 1 mM AdoMet were added to aliquots of eluate
fractions and reaction mixtures were incubated at 37 °C for up to 120
min. Reactions were stopped by the addition of 0.2 M CuCl and heating
to 100 °C for 5 min (29). Denatured proteins were removed by centrif-
ugation and supernatants were oxidized with H2O2 (final concentration
10%). Aliquots of oxidized supernatants were analyzed by TLC as
previously described (30). Fractions that contained the highest levels of
the activity that converted arsenite to methylated and dimethylated
products were pooled and applied to a column of an S-adenosyl-L-
homocysteine-Sepharose affinity gel that was prepared by the method
of Reeve and co-workers (31). The chromatographic gel was fully equil-
ibrated with 50 mM Na phosphate buffer containing 5 mM GSH, 1 mM
DTT, and 5% (v/v) glycerol, pH 7.4. After application of high activity
fractions, the gel bed was washed with 5 column volumes of 50 mM
sodium phosphate buffer containing 5 mM GSH, 1 mM DTT, and 5% (v/v)
glycerol, pH 7.4. The arsenite methylating activity was eluted by addi-
tion of 1 mM AdoMet to the eluting buffer. Fractions containing the
highest arsenic methylating activity were pooled and stored at 20 °C.
Anion Exchange Chromatography, Hydride Generation, Atomic Flu-
orescence Spectrometry—The enzyme-catalyzed conversion of methyl-
arsine oxide to dimethylated arsenic was examined by the method of
Zhang and associates (32). Aliquots of reaction mixtures were chro-
matographed on an anion-exchange column (Supelcosil LC-SAX, 250
mm  4.6 mm, Supelco) using 30 mM potassium phosphate buffer, pH
4.5, as the mobile phase (1 ml/min). Arsines of the separated species
were generated and detected using a Millennium Excalibur atomic
fluorescence spectrometer (PS Analytical, Kent, England).
Peptide Sequence Analysis—SDS-PAGE of pooled active fractions
from S-adenosyl-L-homocysteine-Sepharose affinity chromatography
identified one Coomassie Blue-reactive band. This band was excised
from the gel, transferred to a siliconized tube, and was washed and
destained overnight in 200 l of 50% methanol. Gel pieces were then
dehydrated in acetonitrile and rehydrated in 30 l of 10 mM DTT in 0.1
FIG. 1. Purification of S-adenosyl-L-methionine:arsenic(III)
methyltransferase. Fractions from purification scheme were electro-
phoresed on a 5–20% polyacrylamide gradient and gel stained with
Coomassie Brilliant Blue. Lane 1, rat liver cytosol; Lane 2, acidified
cytosol; Lane 3, pooled active fractions from chromatofocusing gel chro-
matography; Lane 4, pooled active fractions from S-adenosylhomocys-
teine-Sepharose gel chromatography; Lane 5, molecular weight
markers.
TABLE I






Cytosol 1200 0.16 192 1
Acidified cytosol 678 0.48 325 3





0.76 1490 1132 9312
a Specific activity expressed as pmols of methylated and dimethylated arsenic formed per mg of protein in a reaction mixture containing 0.1 M
arsenite that was incubated at 37 °C for 45 min.
b Total activity (picomols of methylated and dimethylated arsenic formed) is the product of the specific activity of a fraction and the total protein
content of that fraction.
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M ammonium bicarbonate. After reduction for 30 min at room temper-
ature, the DTT-containing solution was removed and the sample was
alkylated in 30 l of 50 mM iodoacetamide in 0.1 M ammonium bicar-
bonate for 30 min at room temperature. The alkylating mixture was
removed and the gel pieces were dehydrated in 100 l of acetonitrile.
After removal of the acetonitrile, the gel pieces were rehydrated in 100
l of 0.1 M ammonium bicarbonate. Gel pieces were again dehydrated in
100 l of acetonitrile. After removal of the acetonitrile, gel pieces were
fully dried by vacuum centrifugation. Dried gel pieces were rehydrated
on ice for 10 min in a solution containing 20 g of trypsin/ml in 0.05 M
ammonium bicarbonate. Excess trypsin-containing solution was re-
moved and an additional 20 l of 0.05 M ammonium bicarbonate was
added. This sample was incubated overnight at 37 °C. Peptides were
extracted from the polyacrylamide gel matrix with two 30-l aliquots of
50% acetonitrile in 5% formic acid. Extracts were combined and evap-
orated to a volume of 25 l for further analysis.
The liquid chromatography-mass spectrometry system consisted of a
Finnigan LCQ ion trap mass spectrometer with a Protana nanospray
ion source that was interfaced with a self-packed Phenomenex Jupiter
10 M C18 reversed-phase capillary column (8 cm  75 m inner
diameter). Samples of the extract (0.5 to 5 l) were injected on the
column that was eluted with an acetonitrile, 0.1 M acetic acid gradient
at a flow rate of 0.25 l/min. The nanospray ion source operated at 2.8
kV. The extracts were analyzed using the instrument’s double play
capability. Here, full scan mass spectra were acquired to determine the
molecular weights of peptides and product ion spectra were acquired to
determine the amino acid sequence in sequential scans. This mode of
analysis yields about 400 CAD spectra of ions that range in abundance
over several orders of magnitude. Data were analyzed by data base
searching using the Sequest search algorithm. Peptides that were not
matched by this algorithm were interpreted manually and searched in
the EST data bases using the Sequest algorithm.
Determination of mRNA Sequence—Total RNA was isolated from the
livers of adult male Fischer 344 rat using Trizol reagent (Invitrogen).
Total RNA was treated with DNase (Invitrogen) and cDNA was made
using Promega Reverse Transcriptase System. A set of degenerate
oligonucleotide primers for use in polymerase chain reactions (PCR)
were designed on the basis of the translation of peptide sequences from
S-adenosyl-L-methionine:arsenic(III) methyltransferase. With these
primers, the cDNA was amplified using Hot Start PCR and Ampli Taq
Gold enzyme (PerkinElmer Life Sciences). PCR products were purified
using QIAquick PCR purification. A 900-base sequence was obtained
and was sequenced at the UNC-CH Automated DNA Sequencing Fa-
cility on a Model 377 DNA Sequencer (Applied Biosystems) using the
ABI PrismTM Dye Terminator Cycle Sequencing Ready Reaction Kit
with AmpliTaq DNA polymerase. Using this sequence information, the
sequences of the 5 and 3 ends were obtained using the GeneRacer
system (Invitrogen). The resulting cDNAs were sequenced, providing
the entire mRNA sequence.
Reverse Transcription (RT)-PCR Analysis of Gene Expression—Adult
male Fischer 344 rats were euthanized by cardiac exsanguination un-
der nembutal anesthesia. Tissues were quickly harvested, snap frozen
in liquid nitrogen, and stored at 65 °C. RNA was also isolated from
two human cell lines. HepG2 cells were grown in an amended Dulbec-
co’s modified Eagle’s medium (4.5 g of glucose and 110 mg of sodium
pyruvate per liter) with 15% fetal bovine serum and UROtsa cells were
grown in RPMI 1640 medium with 10% fetal bovine serum. RNA was
isolated from both cell lines using Trizol reagent. RNA was treated with
DNase (Promega) and further purified with an RNeasy Minikit (Qia-
gen). mRNA was reverse transcribed into cDNA which was used for
PCR reactions for detection of S-adenosyl-L-methionine:arsenic(III)
methyltransferase and -actin. PCR was performed on a PerkinElmer
Geneamp 9700 thermal cycler and PCR products were separated on a
1% agarose gel and stained with ethidium bromide.
RESULTS
Protein Purification and Reaction Characteristics—A combi-
nation of acid treatment of cytosol, chromatofocusing, and af-
finity chromatography on an S-adenosyl-L-homocysteine-
Sepharose gel column allowed 9300-fold enrichment of
S-adenosyl-L-methionine:arsenic(III) methyltransferase activ-
ity from rat liver cytosol (Table I). Notably, the total activity of
S-adenosyl-L-methionine:arsenic(III) methyltransferase recov-
ered in this purification scheme increased as the specific activ-
ity of the fractions increased. The enhanced yield may reflect
removal of an endogenous inhibitor of the enzyme’s activity in
the purification scheme or an altered ratio of enzyme to DTT as
purification progresses. A critical factor in the success of this
purification scheme was inclusion of GSH and DTT in all buff-
ers. Earlier work demonstrated that GSH was critical to the
maintenance of arsenic methylating activity in an in vitro
reaction system that contained rat liver cytosol (33, 34) and
that DTT promoted the dimethylation reaction catalyzed by the
purified rabbit liver protein (10). S-Adenosyl-L-homocysteine-
Sepharose affinity chromatography yielded a single Coomassie
Blue staining band on SDS-PAGE (Fig. 1). This material was
used for studies of the characteristics of arsenic methylation
and for preparation of peptides for amino acid sequence
determination.
Fig. 2A illustrates the time course of the production of meth-
ylated and dimethylated arsenicals in a system that contained
25 g of enzyme, 0.1 M [73As]iAsIII, 1 mM AdoMet, 5 mM GSH,
and 1 mM DTT in 50 mM sodium phosphate buffer with 5% (v/v)
FIG. 2. Production of methylated and dimethylated arsenic by
S-adenosyl-L-methionine:arsenic(III) methyltransferase. A, time
course of methylated (Œ) and dimethylated () arsenic in a reaction
mixture that contained 25 g of S-adenosyl-L-methionine:arsenic(III)
methyltransferase, 0.1 M arsenite, 1 mM AdoMet, 5 mM GSH, and 1 mM
DTT in 50 mM Na phosphate buffer, pH 7.5, with 5% (v/v) glycerol and
was incubated at 37 °C for up to 120 min. Structure of the three-
compartment model used to estimate the overall rates of conversion of
arsenite to methyl arsenic (k2,1) and of methyl arsenic to dimethyl
arsenic (k3,2) shown. B, double-reciprocal plot of the relation between
the concentration of methylarsine oxide (M) and the rate of conversion
of methyl arsenic to dimethyl arsenic (picomoles converted per mg of
protein per minute). The reaction mixture contained 25 g of S-adeno-
syl-L-methionine:arsenic(III) methyltransferase, 0 to 5 M methylarsine
oxide, 0.2 mM AdoMet, 5 mM GSH, and 1 mM DTT in 50 mM Na
phosphate buffer, pH 7.5, with 5% (v/v) glycerol and was incubated at
37 °C for 15 min.
Rat Liver Arsenic(III) Methyltransferase 10797
glycerol, pH 7.4. Here, incubation at 37 °C for intervals up to
120 min lead to the appearance of both methylated species.
Notably, the appearance of methylated arsenic preceded the
appearance of dimethylated arsenical. This pattern was con-
sistent with the stepwise formation of 73As-labeled methylated
arsenic from [73As]iAsIII and of 73As-labeled dimethylated ar-
senic from 73As-labeled methylated arsenic. A three-compart-
ment kinetic model with the structure shown in Fig. 2A was
constructed using SAAMII (version 1.1.1), a program for com-
partmental analysis (SAAM Institute, University of Washing-
ton). This model provided estimates of the overall rates for the
appearance of methylated and dimethylated arsenic in this
assay system. Based on the reduction in the residual sum of
squares, k2,1 was estimated as 0.00443% per minute and k3,2 as
0.183% per minute. Under similar conditions, neither arsenate
(AsV) nor methylarsonic (AsV) acid was methylated (data not
shown). In other studies, the conversion of MAsIIIO to dimethy-
lated arsenic was assessed using anion exchange chromatogra-
phy-hydride generation-atomic fluorescence spectrometry to
quantify the substrate and the product. Here, reaction mix-
tures contained up to 5 M MAsIIIO, 25 g of purified enzyme,
0.2 mM AdoMet, 5 mM GSH, and 1 mM DTT in 50 mM sodium
phosphate, pH 7.4, with 5% (v/v) glycerol. Following incubation
for 15 min at 37 °C, reactions were stopped by snap freezing on
dry ice and stored at 20 °C. A double-reciprocal plot of the
dependence of the reaction rate on the concentration of methy-
larsine oxide is shown in Fig. 2B. This analysis yielded an
FIG. 3. Effect of pH and AdoMet
concentration on the activity of S-
adenosyl-L-methionine:arsenic(III)
methyltransferase. A, effect of AdoMet
concentration on the activity of S-ad-
enosyl-L-methionine:arsenic(III) methyl-
transferase. The concentration of AdoMet
was varied from 0 to 1000 M in a reaction
mixtures that contained 25 g of S-ad-
enosyl-L-methionine:arsenic(III) methyl-
transferase, 0.1 M arsenite, 5 mM GSH,
and 1 mM DTT in 50 mM Na phosphate
buffer, pH 7.5, with 5% (v/v) glycerol
which were incubated at 37 °C for 12 min.
B, effect of pH on the activity of S-ad-
enosyl-L-methionine:arsenic(III) methyl-
transferase. Reaction mixtures with final
pH ranging from 5 to 11 that contained
2.5 g of S-adenosyl-L-methionine:
arsenic(III) methyltransferase, 0.1 M
arsenite, 50 M AdoMet, 5 mM GSH, and 1
mM DTT in 50 mM Na phosphate buffer,
pH 7.5, with 5% (v/v) glycerol were incu-
bated at 37 °C for 15 min.
TABLE II
Amino acid sequences of peptides generated by the trypsin digestion of
purified S-adenosyl-L-methionine:arsenic (III) methyltransferase as
determined by liquid chromatography-mass spectrometry
Peptide Measured molecular mass(MH, Da) Sequence
1 729.2 2 DLAVIAK
2 827.8 2 FVSATFR
3 833.3 2 GVPEYIR
4 846.4 2 IGFCPPR
5 878.2 2 YXNEVXK
6 974.5 2 ILDLGSGSGR
7 1088.5 2 GHXTGIDM(o)TK
8 1242.7 2 LVTANIITVGNK
9 1312.6 2 DVQNYYGNVLK
10 1344.7 2 ELIFDANFTFK
11 1409.7 3 DCYVLSQLVGKK
12 1410.7 3 SLQNVHEEVXSR
13 1608.7 3 CKVVYDGGI—K
14 1731.2 2 EGEAVEVDEETAAXLR
15 2232.2 3 FAHDFLFTPVEASLXAA—
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estimated Km of 250 nM and a Vmax of 68 pmol/mg of protein per
min.
The activity of the purified S-adenosyl-L-methionine:arseni-
c(III) methyltransferase was dependent on the concentration of
AdoMet in the reaction mixture. Because buffer containing 1
mM AdoMet was used to elute the enzyme from S-adenosyl-L-
homocysteine-Sepharose gel, the pooled active fraction in
AdoMet-containing buffer was dialyzed against 50 mM Na
phosphate buffer containing 5 mM GSH, 1 mM DTT, and 5%
(v/v) glycerol, pH 7.4, using dialysis tubing with a nominal
molecular weight cutoff of 12,000. The dialysate was used in a
reaction mixture that contained 25 g of enzyme, 0.1 M
[73As]iAsIII, 5 mM GSH, 1 mM DTT, and up to 1000 M AdoMet
in 50 mM Na phosphate buffer with 5% (v/v) glycerol, pH 7.4.
Following a 12-min incubation at 37 °C, reaction mixtures were
processed for analysis of methylated arsenicals. Fig. 3A shows
the influence of AdoMet concentration on the extent of methy-
lation of arsenic. Maximal conversion of arsenic to methylated
products occurred at 50 M AdoMet; yield fell at higher AdoMet
concentrations. In the absence of added AdoMet, methylated
arsenicals were not detected in reaction mixtures (data not
shown). The pH dependence of the arsenic methylating activity
of the protein was examined over the pH range of 5 to 11 (Fig.
3B). Here, 2.5 g of purified enzyme in 50 mM Na phosphate
buffer containing 0.1 M [73As]iAsIII, 5 mM GSH, 1 mM DTT,
and 5% (v/v) glycerol, pH 7.4, was diluted into 95 l of buffer at
the desired final pH. AdoMet concentration was 50 M in the
final reaction mixture. Substantial activity was found between
pH 7.5 and 10 with peak activity at pH 9.5.
Peptide and cDNA Sequencing—Mass spectrometry of the
purified protein provide 15 unique peptide sequences (Table II).
BLASTP analysis found a high degree of identity between these
peptides and the predicted sequences of two proteins (NCB
accession number NP065602 and NP05733). These proteins of
mouse and human origin, respectively, have been provisionally
identified as methyltransferases and designated as Cyt19. Us-
ing peptide sequence data, a set of degenerate oligonucleotide
primers was designed for PCR and subsequent sequencing of
the products (Table III). Based on initial sequence results,
additional oligonucleotide primers were synthesized to com-
plete the sequencing of the full-length cDNA. The sequence of
the full-length cDNA for S-adenosyl-L-methionine:arsenic(III)
methyltransferase and its conceptual translation are shown in
Table IV. The predicted protein contains 369 amino acids and
has a calculated molecular mass of 41,056.
Expression of S-Adenosyl-L-methionine:Arsenic(III) Methyl-
transferase mRNA—RT-PCR analysis detected S-adenosyl-L-
methionine:arsenic(III) methyltransferase mRNA in rat heart,
adrenal, urinary bladder, brain, kidney, lung, and liver (Fig.
4A). In HepG2 cells, a human hepatoma cell line, this mRNA
was detected after 35 or 45 cycles of amplification. However,
in UROtsa cells, an immortalized cell line derived from normal
human urothelium, S-adenosyl-L-methionine:arsenic(III) me-
thyltransferase mRNA was not detected after 45 cycles of am-
plification (Fig. 4B). Notably, both sets of forward and reverse
primers amplified mRNA in rat tissues and in HepG2 cells and
failed to amplify mRNA in UROtsa cells. The results shown for
rat tissues and HepG2 cells are for the primer sets that gave
maximal amplification.
DISCUSSION
The methylation of arsenicals is a common feature of the
metabolism of this metalloid in organisms ranging in complexity
from microorganisms to humans (35–37). Although reservations
have been expressed concerning the use of the rat in studies of
the systemic disposition of arsenic (38), both rat liver cytosol and
primary rat hepatocytes have been shown to be efficient methy-
lators of arsenic (33, 34, 39). Hence, we used rat liver as the
starting material for the purification of the enzyme that methy-
lates arsenic. A novel enzyme has been purified from rat liver
cytosol that catalyzes the formation of methylated arsenic and
dimethylated arsenic using [73As]iAsIII as the initial substrate.
The high yield of activity in the purification scheme may be due
to removal of endogenous inhibitors or alteration of the enzyme:
DTT ratio. Others have noted the presence of endogenous inhib-
itors for arsenite and methylarsonous acid methyltransferases in
cytosol prepared from the livers of rabbits or marmosets (10, 40).
The pattern of appearance of the methylated arsenicals suggests
that the initial reaction forms methylated arsenic from arsenite;
a second reaction then forms dimethylated arsenic from methy-
lated arsenic. Because the apparent first-order rate constant for
the dimethylation reaction is much larger than that for methyl-
ation, dimethylated arsenic will be the predominant metabolite
in the reaction mixture. An uncharacterized aspect of the reac-
tion scheme catalyzed by S-adenosyl-L-methionine:arsenic(III)
methyltransferase is the mode of reduction of pentavalent ar-
senic in methylarsonic acid, the product of the first oxidative
methylation reaction, to trivalency. The formation of methylar-
sonous acid in the reaction mixture used in the present studies
may depend on the presence of DTT. Zakharyan and associates
TABLE III
Peptide sequences and oligonucleotide primers
Name Description Sequence
mtf1F Peptide QNYYGNVLK

















poly dT Oligonucleotide TTTTTTTTTTTTTTTTTTTTTTTTT
a Degeneracies indicated as R  A  G, Y  C  T, M  A  C, K  G  T, S  G  C, W  A  T, H  A  T  C, N  A  C  G  T.
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(11) reported that DTT strongly stimulated the methylation of
methylarsonous acid by the enzyme purified from rabbit liver.
Omission of DTT from reaction mixtures that contain rat liver
S-adenosyl-L-methionine:arsenic(III) methyltransferase sharply
reduces the conversion of arsenite to methylated products.2 In
cells, this reduction may depend on pentavalent arsenic reduc-
tase (7, 8) or on other endogenous reductants. Kinetic analysis
indicated a high affinity of the enzyme for MAsIIIO (Km  250
nM). Concentrations of MAsIIIO greater than 5 M inhibited the
production of dimethylated arsenic. This finding is consistent
with earlier results showing that high concentrations of MAsIIIO
inhibited the formation of dimethyl arsenic in cultured cells (20).
AdoMet served as the methyl group donor for both reactions.
These results are consistent with evidence that trivalent arseni-
cals are the preferred substrate for this enzyme and that the
pentavalent arsenicals must be reduced enzymatically or non-
enzymatically before methylation (7, 11, 41). Based on estimated
molecular weights, the protein purified from rat liver cytosol
(42.000) is probably not identical with the enzyme purified from
rabbit liver cytosol (60,000) that catalyzes the methylation of
arsenite and methylarsonous acid (10, 11). S-Adenosyl-L-
methionine:arsenic(III) methyltransferase from rat liver differs
kinetically from arsenic methyltransferases purified from rabbit
or hamster liver cytosol. For those enzymes, estimated Km values
for the conversion of MAsIII are orders of magnitude higher than
the Km determined for the rat liver enzyme. Further comparison
of the arsenic methyltransferases awaits the availability of data
on the sequence of the protein purified from rabbit or hamster
liver and on additional kinetic characterization of the enzymes.
Unique arsenic methyltransferases may be expressed in the tis-
sues of different species or multiple enzymes capable of cata-
lyzing this reaction may be expressed in tissues. S-Adenosyl-L-
methionine:arsenic(III) methyltransferase is probably not
identical with previously described proteins that catalyze meth-
ylation of selenium. Among these proteins, the best characterized
is thioether S-methyltransferase (EC 2.1.1.96) which catalyzes
the AdoMet-dependent formation of trimethylselenonium ion
from dimethyl selenide (42). However, the smaller molecular
mass of this enzyme (29.5 kDa) and its dissimilar amino acid
sequence (43) indicate a lack of identity with S-adenosyl-L-
methionine:arsenic(III) methyltransferase. Hsieh and Ganther
(44) described two activities from rat liver and kidney that cata-
lyze the synthesis of dimethyl selenide, a protein from the cyto-
solic fraction with a molecular mass of about 30 kDa, and an
activity in the microsomal fraction that catalyzes this reaction.
The protein purified in the present work is not likely to be
identical with these proteins.
S-Adenosyl-L-methionine:arsenic(III) methyltransferase
mRNA was detected in many rat tissues. Studies in in vitro
systems containing cytosolic fractions prepared from rat liver or
kidney have shown that arsenite is methylated in both tissues
(33, 34, 45). Arsenic methylating activity has also been detected
in cytosolic fractions prepared from mouse liver, kidney, lung,
and testes (46). Both methylated and dimethylated arsenicals
have been detected in livers and kidneys of arsenite-treated rats
(47). Hence, the occurrence of S-adenosyl-L-methionine:arsenic
(III) methyltransferase mRNA in rat tissues is consistent with
evidence for the methylation of arsenic in these tissues. HepG2
cells expressed fairly high levels of S-adenosyl-L-methionine:
arsenic(III) methyltransferase mRNA. These cells are efficient
methylators of arsenite, containing both methylated and di-
methylated products (18). In contrast, UROtsa cells which do not
express this mRNA do not methylate arsenic (20). Thus, in this
immortalized human cell line, absence of expression of S-
2 S. Lin and D. J. Thomas, unpublished observations.
TABLE IV
Nucleotide sequence and conceptual translation of rat liver
S-adenosyl-L-methionine:arsenic(III) methyltransferase
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adenosyl-L-methionine:arsenic(III) methyltransferase mRNA is
associated with a failure to produce methylated arsenicals. The
factors that underlie S-adenosyl-L-methionine:arsenic(III) meth-
yltransferase mRNA gene silencing in UROtsa cells have not
been determined.
Alignment of the mRNA sequences of S-adenosyl-L-methio-
nine:arsenic(III) methyltransferase and human Cyt19 suggested
a close relation between these gene products (Table V). The most
striking difference in amino acid sequences of human Cyt19
(calculated molecular mass of 37,969 Da) and of S-adenosyl-L-
methionine:arsenic(III) methyltransferase (calculated molecular
mass of 41,056 Da) was the N-terminal 31-amino acid sequence
that was found only in the rat protein. This sequence contained 4
cysteine residues that may be critically involved in the binding of
AsIII. The overlapping amino acid sequences of S-adenosyl-L-
methionine:arsenic(III) methyltransferase and of human Cyt19
contained several motifs that have been found in other methyl-
transferases (48). Motif I with a consensus sequence of (V/I/L)(L/
V)(D/E)(V/I)G(G/C)G(T/P)G most closely matched residues 74 to
82 (ILDLGSGSG) in predicted sequences of S-adenosyl-L-
methionine:arsenic(III) methyltransferase and human Cyt19.
These sequences conform to the general consensus for motif I
(hh(D/E)hGXGXG), where h is a hydrophobic amino acid, X is
any amino acid, and the position of glycine residues is strongly
conserved (49). Motif I has been associated with the binding of
AdoMet by the enzyme and mutation of the conserved glycine
residues in motif I in guanidinoacetate methyltransferase abol-
ished its catalytic activity (50). An acidic residue which contrib-
utes to the binding of AdoMet has been found between 17 and 19
residues C-terminal to the end of motif I (48, 50). In S-adenosyl-
L-methionine:arsenic(III) methyltransferase and human Cyt19,
aspartate was found 20 residues C-terminal to the end of motif I.
As in other methyltransferases, this aspartate residue was pre-
ceded by a hydrophobic amino acid, isoleucine. Motif II with the
consensus sequence (P/G)(Q/T)(F/Y/A)DA(I/V/Y)(F/I)(C/V/L) has
been found in other methyltransferases. A sequence containing
FDA was found at residues 286 to 293 (LIFDANFT) in S-ad-
enosyl-L-methionine:arsenic(III) methyltransferase; in human
Cyt19, the cognate sequence was LMFDANFT. As in motif II
sequences from other methyltransferases, these sequences in
S-adenosyl-L-methionine:arsenic(III) methyltransferase and in
human Cyt19 included aromatic amino acid residues in close
proximity to an invariant aspartate residue. Notably, motif II in
S-adenosyl-L-methionine:arsenic(III) methyltransferase and in
human Cyt19 was 203 residues C-terminal to motif I. In other
methyltransferases, the start of motif II is 36 to 90 residues
C-terminal to motif I. The consensus sequence for motif III
(LL(R/K)PGG(R/I/L)(L/I)(L/F/I/V)(I/L)) was identified in neither
S-adenosyl-L-methionine:arsenic(III) methyltransferase nor in
humanCyt19.HumanCyt19couldbeanS-adenosyl-L-methionine-
dependent arsenic(III) methyltransferase.
Genetically determined differences among individuals in the
FIG. 4. Detection of S-adenosylmethionine:arsenic(III) methyltransferase mRNA in tissues and cells by RT-PCR. A, expression of
S-adenosylmethionine:arsenic(III) methyltransferase mRNA in rat tissues. For S-adenosyl-L-methionine:arsenic(III) methyltransferase mRNA,
the primers were 5-TCTGCCCTCCACGTTTGGTCACT-3 (mtf4F/rat, forward) and 5-CTGCCGTCTCCTCATCCACTT-3 (mtf2R/rat, reverse);
the predicted product size was 250 bp. The primers for -actin mRNA were 5-TCATGAAGTGTGACGTTGACATCCGT-3 (forward) and 5-
CCTAGAAGCATTTGCGGTGCACGATG-3 (reverse). The predicted product size was 288 bp. PCR conditions were denaturation (30 s at 95 °C),
annealing (30 s at 60 °C), and extension (30 s at 72 °C) for 35 cycles. For each tissue the PCR product for -actin is shown in Lane a and the PCR
product for S-adenosyl-L-methionine:arsenic(III) methyltransferase is shown in Lane b. HT, heart; AD, adrenal gland; UB, urinary bladder; BR,
brain; KD, kidney; LU, lungs; and LI, liver. X174/HaeIII DNA size markers are shown in the last lane. B, expression of mRNA for S-
adenosylmethionine:arsenic(III) methyltransferase in human cell lines. For S-adenosyl-L-methionine:arsenic(III) methyltransferase in HepG2
cells and UROtsa cells, the primers were 5-ATTTTGGATCTGGGCAGTGGGAGT-3 (mtf3F/rat, forward) and 5-AGTGACCAAACGTG-
GAGGGCAGA-3 (mtf3R/rat, reverse); the predicted product size was 477 bp. The primers for -actin mRNA and predicted product size as in A.
For the amplification of mRNA from HepG2 cells or UROtsa cells, a touchdown PCR protocol with either 35 or 45 cycles of amplification was used.
Conditions for denaturation (30 s at 95 °C) and extension (30 s at 72 °C) were constant for either number of cycles. For 35 or 45 cycles of
amplification, the annealing time was always 30 s; however, the annealing temperature of 65 °C decreased 0.5 °C per cycle for the first 20 cycles.
The annealing temperature was then held at 55 °C for the final 15 or 25 cycles of amplification. The RT-PCR product for S-adenosyl-L-methionine:
arsenic(III) methyltransferase is shown in Lane a and the RT-PCR product for -actin is shown in Lane b. X174/HaeIII DNA size markers are
shown in the first lane.
Rat Liver Arsenic(III) Methyltransferase 10801
capacity to methylate inorganic arsenic to methylated and di-
methylated products could be important determinants of the
risk associated with exposure to this metalloid. Epidemiologi-
cal studies suggest an association between the pattern of ar-
senic-containing metabolites in urine and the occurrence of
arsenic-induced skin lesions (51–53). In particular, a higher
percentage of methylated arsenic in urine has been found in
individuals with arsenic-induced skin lesions, including cancer,
than in individuals without arsenic-induced lesions. Consider-
able interindividual variation has been found in the amounts of
methylated and dimethylated arsenic excreted in urine (54).
This variation could reflect polymorphisms in S-adenosyl-L-
methionine:arsenic(III) methyltransferase that affect the rate
of conversion of methylated arsenic to dimethylated arsenic.
However, differences in the urinary excretion of these metab-
olites may also reflect differences among individuals in the
systemic retention of methylated arsenicals. Studies of the rate
and extent of methylation of arsenite in cultured primary hu-
man hepatocytes have also found severalfold variation among
donors in the fraction of inorganic arsenic that is methylated
(39). These results are consistent with a polymorphism in the
rate of arsenic methylation in cultured human cells. Vahter
(55) has suggested that genotypic differences in the activities of
the enzyme that methylates arsenic or in enzymes involved in
the recycling of homocysteine used in the synthesis of AdoMet
could be the sources of variability among individuals in the
urinary output of methylated arsenicals. To this list could be
added genotypic differences in the activity of the reductases
that convert arsenate and methylarsonic acid to arsenite and
methylarsonous acid (7, 8). Additional studies of polymor-
phisms of S-adenosyl-L-methionine:arsenic(III) methyltrans-
ferase will be required to determine the contribution of this
factor to differences among individuals in metabolism, reten-
tion, and clearance of arsenic. By comparison, genetic poly-
morphisms of other methyltransferases have been linked to
specific phenotypic changes. Single nucleotide polymor-
phisms in the open reading frame of the gene encoding thio-
purine methyltransferase or polymorphic variable tandem
repeat number in the 5-flanking region of this gene have
been linked to altered enzyme activity and differences in
response to chemotherapeutics (56). An analogous polymor-
phism of S-adenosyl-L-methionine:arsenic(III) methyltrans-
ferase in humans could affect the rate of formation and
disappearance of methylated arsenicals in tissues. Given the
unique toxicities of methylated arsenicals, especially those
that contain AsIII (57), genotypic variation in the activity of
S-adenosyl-L-methionine:arsenic(III) methyltransferase
might affect the consequences of chronic exposure to inor-
ganic arsenic.
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